** Shares of Larimar Therapeutics LRMR.O down 10.8% in extended trading to $3.15 as co seeks equity raise
** Bala Cynwyd, Pennsylvania-based biotech commences offering of stock and pre-funded warrants
** It plans to use net offering proceeds to support development of its lead compound, nomlabofusp, and other pipeline candidates, and for working capital and general purposes, including R&D, among other purposes
** Nomlabofusp is co's potential treatment for Friedreich’s ataxia, a rare, degenerative disease that damages the nervous system, primarily affecting the spinal cord and nerves that control muscle movement in the arms and legs
** Leerink Partners and Guggenheim are jt bookrunners for the offering
** Co has ~64 mln shares outstanding giving it roughly $225 mln market cap
** LRMR shares on Tues closed down 3% at $3.53. Stock has gained 22% in Jul, leaving them down ~9% YTD
** All 12 analysts are bullish on LRMR and median PT is $18, LSEG data reflects
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。